Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow, Elı́as Campo, Stefano Pileri, et al.
Blood (2016) Vol. 127, Iss. 20, pp. 2375-2390
Open Access | Times Cited: 6998

Showing 1-25 of 6998 citing articles:

WHO classification of tumours of haematopoietic and lymphoid tissues
Daniel Bell, Frank Gaillard
Radiopaedia.org (2010)
Open Access | Times Cited: 3697
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, et al.
The Lancet (2020) Vol. 396, Iss. 10254, pp. 839-852
Closed Access | Times Cited: 1789
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
Catherine de Martel, Damien Georges, Freddie Bray, et al.
The Lancet Global Health (2019) Vol. 8, Iss. 2, pp. e180-e190
Open Access | Times Cited: 1707
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 11, pp. 1200-1228
Open Access | Times Cited: 1649
Non-Hodgkin lymphoma
Jamés O. Armitage, Randy D. Gascoyne, Matthew A. Lunning, et al.
The Lancet (2017) Vol. 390, Iss. 10091, pp. 298-310
Closed Access | Times Cited: 1073
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Frederick L. Locke, David B. Miklos, Caron A. Jacobson, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 7, pp. 640-654
Open Access | Times Cited: 1013
2016 US lymphoid malignancy statistics by World Health Organization subtypes
Lauren R. Teras, Carol DeSantis, James R. Cerhan, et al.
CA A Cancer Journal for Clinicians (2016) Vol. 66, Iss. 6, pp. 443-459
Open Access | Times Cited: 1000
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Elı́as Campo, Elaine S. Jaffe, James R. Cook, et al.
Blood (2022) Vol. 140, Iss. 11, pp. 1229-1253
Open Access | Times Cited: 944
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling, Elı́as Campo, Olivier Hermine, et al.
Annals of Oncology (2017) Vol. 28, pp. iv62-iv71
Open Access | Times Cited: 693
Infection in Organ Transplantation
J. A. Fishman
American Journal of Transplantation (2017) Vol. 17, Iss. 4, pp. 856-879
Open Access | Times Cited: 640
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Francesco Passamonti, Chiara Cattaneo, Luca Arcaini, et al.
The Lancet Haematology (2020) Vol. 7, Iss. 10, pp. e737-e745
Open Access | Times Cited: 524
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar, Scott R. Solomon, Jon Arnason, et al.
The Lancet (2022) Vol. 399, Iss. 10343, pp. 2294-2308
Closed Access | Times Cited: 515
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 4, pp. 351-363
Open Access | Times Cited: 507
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
Ningni Jiang, Qijie Dai, Xiaorui Su, et al.
Molecular Biology Reports (2020) Vol. 47, Iss. 6, pp. 4587-4629
Open Access | Times Cited: 466
EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies
Manuel Ramos‐Casals, Pilar Brito‐Zerón, Stefano Bombardieri, et al.
Annals of the Rheumatic Diseases (2019) Vol. 79, Iss. 1, pp. 3-18
Open Access | Times Cited: 452
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017
Franz Trautinger, Johanna Eder, Chalid Assaf, et al.
European Journal of Cancer (2017) Vol. 77, pp. 57-74
Open Access | Times Cited: 419
Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Yang Liu, Stefan K. Barta
American Journal of Hematology (2019) Vol. 94, Iss. 5, pp. 604-616
Open Access | Times Cited: 410
The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology
Máire A. Duggan, William F. Anderson, Sean F. Altekruse, et al.
The American Journal of Surgical Pathology (2016) Vol. 40, Iss. 12, pp. e94-e102
Open Access | Times Cited: 398
Epstein–Barr virus-associated lymphomas
Claire Shannon‐Lowe, Alan B. Rickinson, Andrew Bell
Philosophical Transactions of the Royal Society B Biological Sciences (2017) Vol. 372, Iss. 1732, pp. 20160271-20160271
Open Access | Times Cited: 378
Post-Transplantation Lymphoproliferative Disorders in Adults
Daan Dierickx, Thomas M. Habermann
New England Journal of Medicine (2018) Vol. 378, Iss. 6, pp. 549-562
Closed Access | Times Cited: 373
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nathan Fowler, Michael Dickinson, Martin Dreyling, et al.
Nature Medicine (2021) Vol. 28, Iss. 2, pp. 325-332
Closed Access | Times Cited: 368
The Global Landscape of EBV-Associated Tumors
Claire Shannon‐Lowe, Alan B. Rickinson
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 366
Bone marrow niches in haematological malignancies
Simón Méndez‐Ferrer, Dominique Bonnet, David P. Steensma, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 5, pp. 285-298
Open Access | Times Cited: 365
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Umberto Vitolo, Marek Trnĕný, David Belada, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 31, pp. 3529-3537
Closed Access | Times Cited: 363
Unravelling biology and shifting paradigms in cancer with single-cell sequencing
Timour Baslan, James Hicks
Nature reviews. Cancer (2017) Vol. 17, Iss. 9, pp. 557-569
Closed Access | Times Cited: 340
Page 1 - Next Page

Scroll to top